ORMP

Oramed Pharmaceuticals Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-26

Figures on this page computed 2026-11-08 13:01 UTC

Last close

4.13USD

Market data, 2026-11-04

ORMP: weekly closes from 4.48 on 2026-08-14 to 4.13 on 2026-11-04, a move of -7.8%. Prices in USD.

Weekly closes, 2026-08-14 to 2026-11-04

Over that span: -7.8%

Except where said otherwise: 10-K for 2025, filed 2026-03-26

2.5xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001213900-26-034835
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-26
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001213900-26-034835
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-Q for 2025, filed 2026-08-10
The filing itself
n/mNet marginnet income exceeds revenue
Net income exceeds revenue.
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001213900-26-034835
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
-457.7%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001213900-26-034835
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001213900-26-034835
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Margins is the furthest below its sector's middle: 0.06 against 0.41 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.91x

-9.21x

0.77x

n/a

0.74x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

4 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-03-26

Sales0.91x
Its own average over 9 years, 2.2M.
Profit-9.21x
Its own average over 10 years, -7.0M.
Free cash flow0.77x
Its own average over 10 years, -11.9M.
Debtn/a
Its own average over 6 years, 15.3M.
Price0.74x
Its own average over 11 years, 6. Market data, 2026-11-04

Profit is furthest from its own average, at -9.21 times.

The filed years, as a table

Each line is 100 at 2016-08-31, the first year we hold.

Filed year	Sales	Shares in issue
2016-08-31	100.0	n/a
2017-08-31	383.2	n/a
2018-08-31	382.1	n/a
2019-08-31	421.7	n/a
2020-08-31	422.8	n/a
2021-08-31	421.7	n/a
2022-12-31	421.7	100.0
2023-12-31	209.0	104.0
2024-12-31	n/a	104.8
2025-12-31	312.0	108.8

How sales was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001213900-26-034835
Reported in: USD

The filing itself

How shares in issue was got

Source: filed
Statement: income
Fiscal year: 2025
Accession: 0001213900-26-034835
Reported in: USD

The filing itself

Figures behind the shape

Growth

-5.9%

faster is higher, placed against 4,950 companies as of 2026-11-07

Five-year revenue growth rate-5.9%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Five-year EPS growth rate22.3%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
One-year change in net income436.0%
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Returns on capital

32.1%

higher is higher, placed against 5,089 companies as of 2026-11-07

Return on invested capitaln/a
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001213900-26-034835
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-Q for 2025, filed 2026-08-10
The filing itself
Return on equity32.1%
Net Income / Shareholders' Equity x 100
Source
computed
Fiscal year
2025
Accession
0001213900-26-034835
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
Return on assets27.7%
Net Income / Total Assets x 100
Source
computed
Fiscal year
2025
Accession
0001213900-26-034835
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-Q for 2025, filed 2026-08-10
The filing itself

Margins

0.7%

wider is higher, placed against 3,412 companies as of 2026-11-07

Gross margin0.7%
Gross Profit / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001213900-26-034835
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
Operating margin-754.4%
Operating Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001213900-26-034835
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
Net marginn/mnet income exceeds revenue
Net income exceeds revenue.
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001213900-26-034835
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
Free cash flow margin-457.7%
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001213900-26-034835
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself

Price

2.5x

cheaper is higher, placed against 4,362 companies as of 2026-11-07

Price to earnings2.5x
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001213900-26-034835
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-26
The filing itself
Price to book0.8x
Price / Book Value per Share, where BVPS = Shareholders' Equity / Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001213900-26-034835
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-26
- computed
- 10-K for 2025, filed 2026-03-26
The filing itself
EV to EBITDAn/a
We do not hold this figure for this company, so there is nothing to place.
Enterprise Value / EBITDA, where EV = Market Cap + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001213900-26-034835
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
- 10-Q for 2025, filed 2026-08-10
- 10-K for 2025, filed 2026-03-26
The filing itself
Price to sales ratio81.9x
Market Cap / Revenue, where Market Cap = Price x Diluted Shares
Source
computed
Fiscal year
2025
Accession
0001213900-26-034835
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself

Safety

6.98

safer is higher, placed against 3,227 companies as of 2026-11-07

Debt to equityn/a
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001213900-26-034835
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
Current ratio6.9810-Q for 2025, filed 2026-08-10
Current Assets / Current Liabilities
Source
computed
Fiscal year
2025
Accession
0001213900-26-087361
Reported in
USD
- 10-Q for 2025, filed 2026-08-10
- 10-Q for 2025, filed 2026-08-10
The filing itself
Interest coveragen/a
We do not hold this figure for this company, so there is nothing to place.
Operating Income / Interest Expense
Source
computed
Fiscal year
2025
Accession
0001213900-26-034835
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
Altman Z-Score2.79
1.2 x A + 1.4 x B + 3.3 x C + 0.6 x D + 1.0 x E (A=WC/TA, B=RE/TA, C=EBIT/TA, D=MktCap/TL, E=Rev/TA)
Source
computed
Taken on
2026-11-07
Reported in
USD
- Computed from the 10-K for 2025, filed 2026-03-26
- Computed from the 10-K for 2025, filed 2026-03-26
- Computed from the 10-K for 2025, filed 2026-03-26
- Computed from the 10-K for 2025, filed 2026-03-26
- Computed from the 10-K for 2025, filed 2026-03-26

What it pays out

n/a

We do not hold this figure for this company, so there is nothing to place.

more, and better covered, is higher, with no cohort held

Dividend yieldn/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed
Payout ration/a
We do not hold this figure for this company, so there is nothing to place.
Common Dividends Paid / Net Income x 100, both from the latest filed fiscal year
Source
computed
Fiscal year
2025
Accession
0001213900-26-034835
Reported in
USD
- 10-K for 2025, filed 2026-03-26
- Computed from the 10-K for 2025, filed 2026-03-26
- 10-K for 2025, filed 2026-03-26
The filing itself
Dividend cover ration/a
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Share a finding

A link to the finding, not to you: it carries nothing about your account.